This trial is evaluating the effectiveness of a targeted therapy (Isatuximab) for patients with newly diagnosed multiple myeloma, who are unable to have a transplant and have had an inadequate response to treatment with lenalidomide and dexamethasone.
This trial is treating patients with Multiple Myeloma.
This is a systemic therapy.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
- You have been diagnosed with cancer, but have not received any treatment.
- You have had a certain type of treatment or surgical procedure.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A prospective Phase II study of Isatuximab Rescue for Inadequate response to Lenalidomide and Dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma
Other Non-Commercial Sponsor
Patients eligible to participate in this trial will initially receive orally administered Lenalidomide on Days 1-21 of a 28 day cycle and orally administered Dexmaethasone on Days 1, 8, 15 and 22 of the 28 day cycle. Blood tests will assess the level of response of the multiple myeloma to the treatment after 4, 6 or 9 cycles of treatment. If the patient has not had partial or complete response they will also receive intravenous administration of Isatuximab, which will be administered weekly for the first month and fortnightly thereafter. Treatment will continue until disease progression while receiving Isatuximab or unacceptable toxicity occurs.
Recruiting Hospitals Read More